Metabolic assessment in liver microsomes by co-activating cytochrome P450s and UDP-glycosyltransferases

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 3, 2003, Pages 223-232

  Yan, Zhengyin ^a   Caldwell, G W ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

CYPs; Metabolism; UGTs and microsomes

Indexed keywords

1 NAPHTHOL; 4 NITROPHENOL; ACENOCOUMAROL; ALAMETHICIN; CLOTRIMAZOLE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DRUG METABOLITE; GLYCOSYLTRANSFERASE; IMIPRAMINE; MEPHENYTOIN; MIDAZOLAM; NICARDIPINE; PARACETAMOL; PHENACETIN; TESTOSTERONE; TOLBUTAMIDE; TRAMADOL; TRANYLCYPROMINE; TRIFLUOPERAZINE; UMBELLIFERONE; URIDINE DIPHOSPHATE; URIDINE DIPHOSPHATE GALACTOSE;

ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG SCREENING; DRUG STABILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME METABOLISM; MOUSE; NONHUMAN;

EID: 0141625129     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190489     Document Type: Article

References (26)

1. Bertrand, M.; Jackson, P.; Walther, B. (2000). Rapid assessment of drug metabolism in the drug discovery process. Europ. J. of Pharm. Sci., 11 (suppl. 2), S61-S72.
2. Thompson, T. N. (2001). Optimization of metabolic stability as a goal of modern drug design. Med. Res. Rev., 21(5), 412-449.
3. Yan, Z.; Caldwell, G.W. (2001). Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Curr. Top. Med. Chem., 1(5), 403-425.
4. Venkatakrishnan, K.; Von Moltke, L. L.; Greenblatt, D. J. (2001). Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J. of Clin. Pharmaco, 41(11), 1149-1179.
5. Lin, J. H.; Wong, B. K. (2002). Complexities ofglucuronidation affecting in vitro-in vivo extrapolation. Curr. Drug Met., 3(6), 623-646.
6. Ethell, B.T.; Beaumont, K.; Rance, D.J.; Burchell, B. (2001). Use of cloned and expressed human UDP-glucuronosyltransferases for the assessment of human drug conjugation and identification of potential drug interactions. Drug Metab. Dispos., 29(1), 48-53.
7. Yokota, H.; Yuasa, A.; Sato, R. (1992). Topological disposition of UDP-glucuronyltransferase in rat liver microsomes. J. of Biochem, 112(2), 192-196.
8. Meech, R.; Mackenzie, P. I. (1998). Determinants of UDP-glucuronosyltransferase membrane association and residency in the endoplasmic reticulum. Arch. of Biochem. Biophy, 356(1), 77-85.
9. Ethell, B.T.; Anderson, G.D.; Beaumont, K.; Rance, D.J.; Burchell, B. (1998). A universal radiochemical high-performance liquid chromatographic assay for the determination of UDP-glucuronosyltransferase activity. Anal. Biochem, 255(1), 142-147.
10. Fulceri R; Banhegyi G; Gamberucci A; Giunti R; Mandl J; Benedetti A. (1994). Evidence for the intraluminal positioning of p-nitrophenol UDP-glucuronosyltransferase activity in rat liver microsomal vesicles. Arch. of Biochem. Biophy, 309(1), 43-46.
11. Trapnell, C. B.; Klecker, R. W.; Jamis-Dow, C.; Collins, J. M. (1998). Glucuronidation of 3′-azido-3′-deoxythymidine (zidovadine) by human liver microsomes: Relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. Antimicrobial Agents Chemother, 42(7), 1592-1596.
12. Fisher, M. B.; Campanale, K.; Ackermann, B. L.; Vandenbranden, M.; Wrighton, S. A. (2000). In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab. Dispos., 28(5), 560-566.
13. Yan, Z.; Caldwell, G. W.; Wu, W. N.; McKown, L. A.; Rafferty, B.; Jones, W.; Masucci, J. A. (2002). In vitro identification of metabolic pathways and cytochrome P450 enzymes involved in the metabolism of etoperidone. Xenobiotica, 32(11), 949-962.
14. Yuan, R.; Madani, S.; Wei, X. X.; Reynolds, K.; Huang, S. M. (2002). Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab. Dispos., 30(12), 1311-1319.
15. Paar, W. D.; Frankus, P.; Dengler, H. J. (1992). The metabolism of tramadol by human liver microsomes. Clin. Investig., 70(8), 708-710.
16. Wu, W. N.; McKown, L. A.; Liao, S. (2002). Metabolism of the analgesic drug ULTRAM (tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolites. Xenobiotica, 32(5), 411-425.
17. Wu, W. N.; McKown, L. A.; Gauthier, A. D.; Jones, W. J.; Raffa, R. B. (2001). Metabolism of the analgesic drug, tramadol hydrochloride, in rat and dog. Xenobiotica, 31(7), 423-441.
18. Lave, T.; Dupin, S.; Schmitt, C.; Valles, B.; Ubeaud, G.; Chou, R. C.; Jaeck, D.; Coassolo, P. (1997). The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm. Res., 14(2), 152-155.
19. Obach, R. S. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 27(11), 1350-1359.
20. Hagen N.; Olsen A. K.; Andersen J. V.; Tjornelund J.; Hansen S. H. (2002). Characterization of mixtures of recombinant human cytochrome p450s as a screening model for metabolic stability in drug discovery. Xenobiotica, 32(9), 749-759.
21. Clarke, S. E.; Jeffrey, P. (2001). Utility of metabolic stability screening: comparison of a vitro and in vivo clearance. Xenobiotica, 31(8/9), 591-598.
22. Lau, Y. Y.; Krishna, G.; Yumibe, N. P.; Grotz, D. E.; Sapidou, E.; Norton, L.; Chu, I.; Chen, C.; Soares, A. D.; Lin, C. C. (2002). The use of in vitro metabolic stability for rapid selection of compounds in early discovery based on their expected hepatic extraction ratios. Pharm. Res., 19(11), 1606-1610.
23. Obach, R. S. (2001). The prediction of human clearance from hepatic microsomal metabolism data. Curr. Opin. in Drug Disc. & Develop., 4(1), 36-44.
24. Naritomi, Y.; Terashita, S.; Kimura, S.; Suzuki, A.; Kagayama, A. (2001) ; Sugiyama, Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab. Dispos., 29(10), 1316-1324.
25. Lave, T.; Dupin, S.; Schmitt, C.; Chou, R. C.; Jaeck, D.; Coassolo, P. (1997). Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J. of Pharm. Sci., 86(5), 584-590.
26. Soars, M.G.; Burchell, B.; Riley, R.J. (2002). In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J. of Pharm. Experi. Thera., 301(1), 382-390.